Can I Take Magnesium with Fosamax (Alendronate)?

Fosamax is the brand name for alendronate sodium, an oral bisphosphonate approved by the FDA for osteoporosis in postmenopausal women and men, glucocorticoid-induced osteoporosis, and Paget disease of bone. Magnesium is an essential mineral available over the counter in several supplement forms (oxide, citrate, glycinate, malate). The two are commonly taken together because people on osteoporosis therapy are also told to attend to overall bone-mineral status.

Magnesium can be taken alongside Fosamax, but not at the same time. Alendronate has an oral bioavailability of roughly 0.6% even under ideal fasting conditions, and divalent cations such as magnesium bind to the drug in the gut and can drive that already-small absorbed fraction toward zero. [1] This is a pharmacokinetic (absorption-level) interaction, not a pharmacodynamic one: magnesium does not change what alendronate does once it reaches bone, and alendronate does not alter magnesium's own physiology. Separating the two by at least 30 minutes, per the FDA label's general instruction for all supplements, food, and other medications taken with alendronate, avoids the interaction entirely. [1]

At a glance

  • Core answer / Take magnesium, but not within 30 minutes of Fosamax
  • Interaction type / Pharmacokinetic (absorption-level), not pharmacodynamic
  • Mechanism / Mg²⁺ can chelate alendronate and reduce GI absorption; well documented for calcium co-administration, plausible by chemical analogy for magnesium
  • Alendronate oral bioavailability / Approximately 0.6% under fasting conditions, per FDA label
  • Recommended separation window / At least 30 minutes after alendronate (FDA label minimum for all supplements/medications/food)
  • Magnesium forms / Oxide has poor absorption and more GI upset; glycinate, citrate, and malate are generally better tolerated
  • Adult magnesium RDA / 320 mg/day (women), 420 mg/day (men) per NIH Office of Dietary Supplements
  • Depletion risk / Long-term PPI use and some diuretics can lower magnesium status; exact magnitude varies and should be checked with labs, not assumed
  • Prescribing language / FDA label instructs patients not to take other medications or supplements within 30 minutes of alendronate

Why timing, not safety, is the real question

The useful question here is not "is magnesium safe with Fosamax" (it is) but "does taking magnesium at the wrong time silently cancel the drug." Alendronate's absorption margin is so thin to begin with that a co-ingested mineral supplement is capable of reducing an already-tiny absorbed dose close to nothing, without producing any symptom that would tip a patient off. That is the practical risk: not toxicity, but a bone drug that never reaches bone.

The mechanism: why divalent cations block alendronate absorption

Alendronate carries a bisphosphonate structure with phosphonate groups that readily coordinate with divalent metal cations, including calcium, magnesium, and iron. A pharmacokinetic study of oral alendronate bioavailability found that co-administering the drug with coffee or orange juice, or with calcium, substantially reduced its absorption compared with dosing in water alone. [2] Magnesium is chemically similar enough to calcium in this context that the same chelation risk is generally assumed to apply, which is why the FDA label instruction to avoid all supplements and food within 30 minutes of alendronate is written broadly rather than naming only calcium. [1] A magnesium-specific pharmacokinetic study confirming the exact magnitude of reduced alendronate absorption was not identified for this article; the interaction is treated here as established by mechanism and by the label's general precaution, not by a magnesium-specific absorption trial.

Because alendronate's bioavailability is only about 0.6% even under ideal conditions, this is not a case where a partial reduction is a minor inconvenience. [1] It can be the difference between a therapeutic dose and one that does essentially nothing.

Magnesium's own relationship to bone health

Magnesium is stored substantially in bone tissue and participates in the mineralization process, and low dietary magnesium intake has been associated with lower bone mineral density in observational studies. A Framingham Osteoporosis Study analysis found that higher dietary magnesium (along with potassium and fruit and vegetable intake) was associated with greater bone mineral density in older men and women after adjustment for other nutrients. [3] This is observational evidence of association, not a randomized trial showing that magnesium supplementation increases bone density or prevents fractures.

A narrative review on magnesium status in the United States has argued that a meaningful share of the population does not meet recommended magnesium intake, and that this shortfall is likely underappreciated as a contributor to chronic disease risk, including bone health. [4] Specific current percentages of population-level inadequacy (for example, exact figures from more recent national nutrition surveys) were not independently verified for this article and should be confirmed against primary survey data before being stated as precise numbers.

A separate randomized trial examined oral magnesium supplementation and physical performance in older women in a structured exercise program. [5] That trial speaks to physical function, which is relevant to fall risk, rather than directly to bone mineral density or fracture rates, and it should not be cited as fracture-outcome evidence.

Who should pay closer attention to magnesium status

Patients on alendronate are frequently older adults who are also on medications known to affect magnesium status.

Proton pump inhibitors. The FDA issued a drug safety communication warning that long-term PPI use (generally more than a year) has been associated with hypomagnesemia, in some cases severe enough to require magnesium replacement. [6] Patients on both a PPI and alendronate warrant periodic attention to magnesium status, discussed with a prescriber rather than assumed.

Diuretics. Loop and thiazide diuretics are recognized causes of increased magnesium loss through the kidney, discussed in the NIH Office of Dietary Supplements magnesium fact sheet. [7] The exact magnitude of magnesium level reduction varies by drug, dose, and individual, and a specific numeric estimate is not asserted here.

Dietary intake in older adults. Magnesium intake below recommended levels is common enough in the general population that clinicians reasonably consider supplementation in older patients, though the precise current prevalence should be checked against up-to-date national survey data rather than assumed from older reviews. [4] [7]

How to schedule both without losing the drug's effect

  1. Take alendronate first thing in the morning with a full glass of plain water only, on an empty stomach, per the FDA label. [1]
  2. Stay upright and avoid food, beverages other than plain water, and any other medication or supplement for at least 30 minutes. [1]
  3. Take magnesium at a different time of day. Bedtime or with the evening meal is the simplest option because it removes any risk of overlap.
  4. If morning is the only practical time for magnesium, wait a minimum of 30 minutes after alendronate, consistent with the FDA label's general separation instruction for all supplements. [1]

Evidence-status assessment: magnesium and alendronate

ClaimStatusBasis
Alendronate has very low oral bioavailability (~0.6%) even when fastingEstablishedFDA-approved label [1]
Coffee, orange juice, and calcium co-administration substantially reduce alendronate absorptionEstablishedPharmacokinetic bioavailability study [2]
Magnesium specifically chelates alendronate and reduces its absorption to a similar degree as calciumPlausible, not directly established by a magnesium-specific trial in the sources reviewed hereChemical analogy to calcium/divalent cation chelation; general FDA label precaution covering all supplements [1][2]
A 30-minute separation prevents clinically meaningful absorption lossEstablished as the FDA label's minimum instruction; not independently quantified for magnesium aloneFDA label [1]
Dietary magnesium intake correlates with bone mineral densityEstablished as an epidemiological association, not causationFramingham Osteoporosis Study cohort analysis [3]
Magnesium supplementation improves bone density or reduces fracture risk on its ownNot establishedNo randomized fracture-outcome trial of magnesium monotherapy was identified in the sources for this article
PPIs and diuretics can lower magnesium statusEstablished as a class effect; individual magnitude not establishedFDA safety communication [6]; NIH ODS fact sheet [7]
A specific national prevalence figure for magnesium inadequacy in older US adultsRequires verification against current primary survey dataNarrative review discusses the issue generally but predates more recent survey cycles [4]

What a clinician or pharmacist should verify before relying on this page: the exact wording of any current Fosamax label section on drug/food/supplement interactions (labels are periodically revised), the patient's actual serum magnesium and calcium status if on a PPI or diuretic, and whether a specific bone-turnover-marker or DXA monitoring protocol applies to that patient's clinical situation rather than a general guideline summary.

Monitoring: what a clinician might check

Bone turnover markers such as serum CTx (C-terminal telopeptide) or urine NTx are sometimes used to assess whether a bisphosphonate is being absorbed and is suppressing bone resorption, and osteoporosis management guidelines discuss their use alongside periodic DXA scanning to track treatment response. [8] The exact interval and the magnitude of change considered meaningful vary by guideline and by clinical context; a specific numeric threshold should be confirmed with the prescribing clinician rather than applied generically, since this draft has not independently verified a single universal cutoff from a primary guideline document.

If bone density shows no improvement, or bone turnover markers do not fall as expected after a reasonable period of reported adherence, a clinician may reasonably ask about supplement timing, since unrecognized co-ingestion of minerals is one plausible, correctable explanation among several (others include true nonresponse, missed doses, or an unrelated cause of bone loss).

Special situations

Baseline hypocalcemia. The FDA label lists hypocalcemia as a contraindication to starting alendronate. [1] Because significant magnesium deficiency can impair parathyroid hormone secretion and contribute to hypocalcemia, correcting a documented magnesium deficiency before starting alendronate is a reasonable clinical step, to be guided by the prescribing clinician rather than self-managed.

Glucocorticoid-induced osteoporosis. Alendronate is a guideline-recommended option for patients on long-term glucocorticoids at doses and durations meeting specific criteria (for example, a threshold prednisone dose maintained for a period of months), per American College of Rheumatology guidance. [9] Glucocorticoids can also affect mineral absorption, which is a reason clinicians in this population pay attention to both calcium and magnesium status, again with timing relative to alendronate managed the same way as in any other patient.

Older adults on multiple medications. A patient on alendronate, a PPI, a diuretic, and a multivitamin has a real scheduling problem, not a safety problem. The most reliable fix in practice is a written, clock-time schedule: alendronate on waking with plain water, everything else held for at least 30 minutes, and magnesium moved to a fixed evening time.

What is not established

This page distinguishes what is established from what is plausible but unverified. Established: alendronate's very low bioavailability, the FDA label's general 30-minute separation instruction, and the observed reduction in alendronate absorption from co-administered calcium, coffee, or orange juice. Plausible by mechanism but not confirmed by a magnesium-specific pharmacokinetic study in the sources reviewed: the exact magnitude of absorption loss from magnesium specifically. Not established: that magnesium supplementation alone changes fracture risk, or a single universal numeric threshold for bone turnover marker response timing that applies to every patient. Readers and clinicians relying on specific numeric monitoring targets should confirm them against the current primary guideline text.

Practical summary

  1. Take alendronate on an empty stomach with plain water, first thing in the morning, and remain upright for at least 30 minutes without other food, drink, or supplements. [1]
  2. Move magnesium to a different time of day, such as bedtime, to avoid the interaction altogether.
  3. If magnesium must be taken in the morning, wait at least 30 minutes after alendronate.
  4. If you take a PPI or a diuretic long-term, ask your prescriber whether checking serum magnesium periodically makes sense for you. [6][7]
  5. If bone density or turnover markers are not improving as expected, ask your pharmacist or prescriber to review your full supplement schedule, including timing.
  6. Seek prompt medical attention for symptoms that could reflect severe magnesium deficiency (muscle cramps, weakness, irregular heartbeat) or for chest pain, difficulty swallowing, or severe heartburn after taking alendronate, which can indicate esophageal irritation requiring evaluation.

Frequently asked questions

Can I take magnesium while on Fosamax?
Yes, but not at the same time. Magnesium should be separated from alendronate by at least 30 minutes, consistent with the FDA label's general instruction to avoid taking other supplements, food, or medications close to an alendronate dose. Taking magnesium at bedtime is a simple way to avoid the issue entirely.
Does magnesium interact with Fosamax?
There is a pharmacokinetic interaction risk: magnesium is a divalent cation, and this class of minerals is known to reduce alendronate absorption when taken at the same time, as shown for calcium in bioavailability studies. Alendronate's absorption is already very low (about 0.6 percent), so any further reduction can make the dose ineffective. Separating the doses avoids the problem.
How long should I wait to take magnesium after Fosamax?
The FDA label requires at least 30 minutes between alendronate and any other supplement, food, or medication. Taking magnesium at a different time of day, such as bedtime, removes the need to time it closely at all.
What type of magnesium supplement is best to take with Fosamax?
Any magnesium form is compatible with Fosamax as long as timing is separated. Magnesium oxide is poorly absorbed and tends to cause more gastrointestinal upset; glycinate, citrate, and malate are generally better tolerated, which can matter for patients who already have esophageal sensitivity from alendronate.
Does Fosamax cause magnesium deficiency?
There is no established mechanism by which alendronate itself depletes magnesium. Magnesium depletion in patients on alendronate is more commonly related to other factors, such as long-term proton pump inhibitor or diuretic use.
What happens if I accidentally take magnesium at the same time as Fosamax?
That dose of alendronate may not have been absorbed well. For a once-weekly dosing schedule, an occasional missed or ineffective dose is not typically an emergency; resume the normal schedule and adjust magnesium timing going forward. Do not double the next dose. If you have ongoing concerns, contact your prescriber or pharmacist.
How do I know if my Fosamax is working despite taking magnesium?
Clinicians sometimes use bone turnover markers or follow-up DXA scans to assess response, and may ask about supplement timing if response is weaker than expected. Specific numeric targets and timing for these tests should come from your own prescriber rather than a general reference, since practices vary.

References

  1. Merck & Co. Fosamax (alendronate sodium) Prescribing Information, as generally described in FDA-approved labeling for alendronate (specific label document link unavailable).
  2. Gertz BJ, Holland SD, Kline WF, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. 1995;58(3):288-298. https://pubmed.ncbi.nlm.nih.gov/7554702/
  3. Tucker KL, Hannan MT, Chen H, Cupples LA, Wilson PW, Kiel DP. Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. Am J Clin Nutr. 1999;69(4):727-736. https://pubmed.ncbi.nlm.nih.gov/10197575/
  4. Rosanoff A, Weaver CM, Rude RK. Suboptimal magnesium status in the United States: are the health consequences underestimated? Nutr Rev. 2012;70(3):153-164. https://pubmed.ncbi.nlm.nih.gov/22364157/
  5. Veronese N, Berton L, Carraro S, et al. Effect of oral magnesium supplementation on physical performance in healthy elderly women involved in a weekly exercise program: a randomized controlled trial. Am J Clin Nutr. 2014;100(3):974-981. https://pubmed.ncbi.nlm.nih.gov/25008857/
  6. FDA has previously communicated that long-term proton pump inhibitor use can be associated with low magnesium levels; readers should consult current FDA guidance directly (specific communication link unavailable).
  7. National Institutes of Health Office of Dietary Supplements. Magnesium: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/
  8. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis. Endocr Pract. 2020;26(Suppl 1):1-46. https://pubmed.ncbi.nlm.nih.gov/32427503/
  9. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res. 2017;69(8):1095-1110. https://pubmed.ncbi.nlm.nih.gov/28585410/
  10. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535-1541. https://pubmed.ncbi.nlm.nih.gov/8950879/
  11. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. https://pubmed.ncbi.nlm.nih.gov/30907953/
Evidence overview for supplements alendronate: Can I Take Magnesium with Fosamax (Alendronate)?